"A monoclonal antibody that specifically recognizes m⁶A nucleoside" Espuny, R., Castro, A., Codony, C., Eritja, R., Bach-Elias, M. *Nucleosides & Nucleotides*, 17(12), 2189-2197 (1998). doi: 10.1080/07328319808004309

A MONOCLONAL ANTIBODY THAT SPECIFICALLY RECOGNIZES m⁶A NUCLEOSIDE

Ruth Espuny, Anna Castro, Carles Codony, Ramon Eritja[#] and Montserrat Bach-Elias^{*}

^{*}CID-CSIC. c/Jorge Girona Salgado 18-26 08034 Barcelona, Spain. Email: mbebmc@cid.csic.es. [#]present address: EMBL. Meyerhofstrasse 1. Postfach 10.2209. Heidelberg, Germany.

Abstract: A hybridoma against the nucleoside m⁶A has been obtained from mouse spleen. This hybridoma was named H65 and it secretes monoclonal antibodies anti-m⁶A. The competition assays showed that the monoclonal antibody was highly specific for m⁶A nucleoside.

Modified nucleosides are a common feature of RNA molecules (for a review see ref. 1). In some cases, these modified nucleosides are characteristic of some RNA molecules and they have been used to classify the RNAs. One example is the nucleoside trimethylguanosine, which is a hallmark of UsnRNAs (1).

Specific nucleosides are modified post-transcriptionally, but in many cases little is known about the enzymes and the sequences or structural requirements for the modification of a specific nucleoside. N⁶-methyladenosine (m⁶A) is present at internal positions of tRNA, rRNA, mRNA and snRNA molecules (1). The consensus sequence Pu(G/A)AC(U/A)-A being methylated- in the pre-mRNAs has been described as the recognition site for the methyltransferase (2). In each pre-mRNA molecule, one in every three adenosines are usually methylated (2-5). Recently, using a rabbit reticulocyte translation system it has been shown that internal m⁶A increases the *in vitro* translation efficiency of dihydrofolate reductase messenger RNA (6). The human N⁶-Adenosine Methyltransferase of the pre-mRNA substrate has been partially purified (7) and it consists of at least three subunits of 30, 200 and 875 kDa. By further purification of the fraction containing the 200 kDa unit, a 70 kDa protein has been isolated, which when sequenced turned out to be a subunit of the human N⁶-Adenosine Methyltransferase (8). Little is known about whether the same methyltransferase methylates all RNAs or there are specific methyltransferases for each class of RNAs. The methylated sequences found in the snRNA, tRNA and rRNA molecules are not similar to those in the mRNAs (9-11). Furthermore, the enzyme that methylates the adenosine in the U6snRNA is different to the mRNA-methyltransferase (11).

FIG. 1. Immune response of the mice to m^6A nucleoside conjugated to BSA. Two Balb/c mice (referred as B4 and B5 in the figure) were immunized with m^6A -BSA following Bochning *et al.* (13). Twenty days after the first immunization, some blood was taken from the mouse tail and sera obtained by centrifugation of the blood. Sera from each animal was diluted 1/50 to 1/10000 in PBS/T and analyzed by ELISA plates coated with m^6A -KLH. Pre-immune sera (referred as NIS in the figure) from each animal was also diluted and analyzed in parallel. Only the OD values obtained with 85 pre-immune serum are indicated in the figure. B4 and B5 serum showed a titer of around 1/8000 and 1/6000, respectively.

The recognition of the adenosine methylation by such a biological tool as an antibody, which is able to distinguish both between methylated and nonmethylated adenosine, and between methylation in different ring positions of nucleosidednucleotides or even hypermethylation, is an important tool to characterize this post-transcriptional mechanism. Polyclonal antibodies antim 6A that recognize the m^6A of UsnRNAs have been described (12). Here we describe a monoclonal antibody anti- m^6A that specifically recognizes m^6A .

Two Balb/c mice (referred as B4 and B5) were immunized with the m^6A -BSA conjugate as described by Bochning *et al.* 1987. Fig. 1 shows the titers obtained with the sera from both mice 20 days after the initial injection and coating the ELISA-wells with the m^6A -KLH conjugate.

The figure also shows the results obtained with the non-immune sera (sera obtained from each mice before immunization). Sera from B4 and B5 showed titers of 118000 and 116000, respectively. The reaction of the sera with the m^6A -KLH conjugate was inhibited when the diluted sera was competed with free m^6A nucleoside (result not shown). This suggests that both animals produce antibodies specific for m^6A , and that they also have serum titers high enough to try to obtain a hybridoma from their B lymphocytes.

Spleenocytes from B4 mouse (B5 mouse died a few days before the fusion experiment) were fused with NS1 myeloma cells. Fourteen days after

the hybridoma fusion, the supernatants of the hybridomas were screened with m⁶A-KLH conjugate and 24 positive wells were selected. Out of these clones, only 13 remained stable and reacted with the m⁶A-KLH conjugate. Three of these hybridomas were cloned three times by limiting dilution, and one stably hybridoma was expanded and referred to as H65. H65 hybridoma stable secretes monoclonal antibodies (IgG1, κ) anti-m⁶A after freezing and defrosting procedures. The reaction of the H65 monoclonal antibody with the m⁶A-KLH conjugate is inhibited using free m⁶A nucleoside.

Figure 2 shows that the inhibition of the reaction increases when larger amounts of free m⁶A nucleoside were added to the solution, thus indicating that the antibody specifically recognizes the m⁶A nucleoside of the conjugate. Cross-reactions with other nucleosides/ nucleotides were studied by competitive ELISA assays with the following nucleosides/ nucleotides: m⁶A (N⁶-methyladenosine); A (adenosine); m₂^{6,6}A (N⁶,N⁶-dimethyladenosine); m¹A (1-methyladenosine); Am (2'-O-methyladenosine); m⁶Ade (N⁶-methyladenine); m⁷G (7-methylguanosine), ATP and GTP (also showed in Figure 2). Only m⁶A resulted in an inhibitory effect at a concentration of 0.01-50 nmols (figure 2); whereas m⁶Ade showed a very low inhibitory effect (10%) with highest concentration of the inhibitor (50 nmols). All the other competitors studied did not inhibit the binding of the antibody to the m⁶A-KLH conjugate.

This property of the H65 monoclonal antibody distinguishes itself from the rabbit polyclonal antibody R1280 obtained in 1987 (12). R1280 significantly cross-reacted with Am (12) whereas H65 monoclonal antibody specifically recognizes 6-monomethyladenosine, since neither adenosine (A) nor N⁶,N⁶-dimethyladenosine (m₂^{6,6}A) inhibited the reaction between the monoclonal antibody and the m⁶A-KLH conjugate. This second property also makes H65 different to R1280, as this polyclonal antibody clearly cross-reacted with both m⁶Ade and m₂^{6,6}A nucleosides (12).

FIG. 2. The specificity of the monoclonal H65 antibody was showed by competition ELISA assay with m⁶A, m₂^{6,6}A, m¹A, Am, m⁶Ade, m⁷G nucleosides and with the ATP, GTP nucleotides. The ELISA plates were coated with m⁶A-KLH at a concentration of 13 μ g/ml, which was maintained in all the competition assays. 100 μ l of the H65 hybridoma supernatant was mixed with increasing amount (0, 0.01, 0.1, 0.5, 1, 5, 10 to 50 nmols in 10 μ l of PBS buffer) of each

nucleoside. A control reaction with no nucleoside was also performed (0 nmols in the figure). The percentage of inhibition was calculated comparing the OD values for each reaction with that obtained with 0 nmols of free nucleoside. An inhibition of around 70% was obtained with 35 nmols of free nucleoside m^6A , and 10% of inhibition with 50 nmols of the nucleoside m^6Ade . Other nucleosides/nucleotides did not inhibit the antibody reaction in this range of concentrations and they are all plotted together in the line marked as "others".

In summary, adenosines methylated at different ring or ribose positions showed a higher rate of competition with the reaction of R1280 and m^6A conjugate than with that of H65 and the conjugate.

The specificity of the H65 monoclonal antibody was further studied by binding assays with a nucleoside column. The nucleoside column was prepared by covalent binding of the m^6A nucleoside ribose to the amino groups of EAH Sepharose 4B resin (13). This method avoided the presence of the carrier proteins (either BSA or KLH) during the binding of the H65 monoclonal antibody to m^6A nucleoside. H65 monoclonal antibodies from either hybridoma supernatant or ascite fluids clearly bound to m^6A -EAH Sepharose 4B resin and bound monoclonal antibodies were then eluted by competition with free m^6A nucleoside (Figure 3).

This result again indicates that the binding is specific and independent of the carrier protein conjugated to the m^6A nucleoside. The purified monoclonal antibody reacted with the m^6A -KLH conjugate in ELISA plates and the reaction was inhibited by free nucleoside. The purified anti- m^6A monoclonal showed the same properties than the crude antibody (both from the supernatant and the ascites fluid) when tested in competition ELISA assays (data not shown).

FIG. 3. The anti- m^6A nucleoside antibodies from the H65 hybridoma bound to m^6A nucleoside columns and were later eluted by competition with free m^6A nucleoside. Lane 1 and 2 show respectively the crude supernatant fraction of the H65 hybridoma before the immunoaffinity chromatography

and the purified monoclonal antibody after loading the supernatant on the m^6A column and eluting with free m^6A nucleoside. H and L mean heavy and light chains of the IgGs.

Finally, a nuclear extract from HeLa cells was immunoprecipitated with the monoclonal antibody H65. 100 μ l of hybridoma supernatant was used (corresponding to 0.2-1 μ g of antibody) in this assay. An antitrimethylguanosine monoclonal antibody (10 μ g) that immunoprecipitates UsnRNAs, was also used as a positive control. The results obtained are shown in figure 4.

As can be seen in the figure 4, H65 immunoprecipitates both U4snRNA and a small amount of U2snRNA. Both of these UsnRNAs contain the m^6A modification. U2snRNA is not easily immunoprecipitated with the antibody, since the m^6A modification is not very accessible to the antibody in this extract (our unpublished results). Besides the antibody did not immunoprecipitate U5snRNA (figure 4), which does not have m^6A modification. The presence of U1 snRNA in the anti- m^6A immunoprecipitates has also been reported with other anti- m^6A antibodies (12). These results indicate that our antibody recognizes the m^6A modification in RNA.

In summary, here we report a monoclonal antibody that specifically recognizes m^6A nucleoside. The antibody did not recognize either A or m^2m^6A .

FIG. 4. Immunoprecipitation of UsnRNAs with the monoclonal antibody H65. Lanes: 1, nonrelated monoclonal antibody (negative control); 2, monoclonal antibody Ab-1 antitrimethylguanosine (14) (10 μ g of antibody) and 3, monoclonal H65 anti- m^6A (100 μ l of supernatant, 0.2-1 μ g of antibody). The band marked with an arrowhead corresponds to 5.8 S ribosomal RNA and is caused by an inespecific reaction of both antibodies (antitrimethylguanosine and anti- m^6A) in these conditions, and it is due to the fact that this RNA is a very good substrate for pCp labeling. As pCp labeling does not allow to quantify RNAs (since different RNAs are differentially labeled with this technique) the intensity of these bands does not reflect the real amount of RNA in the band.

EXPERIMENTAL SECTION

m⁶A-Conjugates and nucleosides/nucleotides

The nucleoside m⁶A (Sigma) was conjugated either to the carrier KLH (keyhole limpet hemocyanin) or to BSA (bovine serum albumin) following the method described by Erlanger and Beiser (15). Other nucleosides/nucleotides used in this work were purchased from Sigma.

Mice immunization and fusions

Two female Balb/c mice were immunized with 400 µg of the m⁶A-BSA conjugate following the method described by Boching *et al.* (immunogen in complete adjuvant on day 0, and immunogen in incomplete adjuvant on days 20, 28, 33, 34 and 35) (13). Both mice rendered good antibody titers (see Fig. 1 in results). The spleenocytes isolated from both mice on day 36 were fused to NS1 myeloma cells (13).

Screening of anti-m⁶A positive clones and hybridoma cloning

14 days after the spleenocyte fusion, the supernatants were screened with ELISA plates coated with m⁶A-KLH conjugate. Hybridomas in positive wells were cloned by limiting dilution. One clone, referred as H65, remained stable after three cloning steps by limiting dilution. This clone was also stable after freezing/thawing treatments.

ELISAs with the m⁶A-KLH conjugate.

Each ELISA well was coated with 50 µg of m⁶A-KLH solution (13 µg/ml) in PBS (20 mM KH₂PO₄ pH 7.4, 140 mM NaCl, 0.02% NaN₃) and incubated overnight at 4 °C. On the next day, the plates were washed three times with PBS/T (PBS with 0.1% Tween 20). The wells were then incubated with the antibody solutions: either 50 µl of mice sera diluted 1/50 to 1/10000 in PBS/T, 100 µl of hybridoma supernatants diluted 1/2 in PBS/T or 100 µl of non-diluted supernatants without dilution. The ELISA plates were then incubated for 90 min at room temperature. Then, the plates were washed three times with PBS/T and each well was incubated for 2 h at room temperature with 50 µl of anti-mouse IgG conjugated to alkaline-phosphatase and diluted 1/1000 in PBS/T. The plates were washed three times with PBS/T and incubated with the substrate solution (50 mM Na₂CO₃/NaHCO₃ pH 9.5, 2 mM MgCl₂ and 1 mg/ml *p*-nitrophenyl-phosphate). The plates were measured at 405-450 nm 30 min after substrate addition.

ELISA competition-assay.

Each ELISA well was coated with 50 µl of m⁶A-KLH solution (13 µg/ml) in PBS (20 mM KH₂PO₄ pH 7.4, 140 mM NaCl, 0.02% NaN₃) and incubated overnight at 4 °C. On the next day, the plates were washed three times with PBS/T. Wells were saturated with a solution containing 0.5% teleostean gelatin in PBS for 1 h at room temperature. The competition solution was prepared as follows: 100 µl of the hybridoma supernatant was incubated with different amounts of each nucleoside (from 0 to 50 nmols, each quantity dissolved in 10 µl of PBS), in different tubes for 1 h at room temperature. After saturation, the ELISA wells were washed three times with PBS/T. Each well was then incubated with one of the competition

solutions (110 µl) for 1 h at room temperature. From this point, the ELISA plates were treated as described above.

Immunoprecipitation assay.

Immunoprecipitation assay was performed as previously described (16). pCp labeling of the UsnRNAs was performed as indicated in the previous publication (16).

ACKNOWLEDGEMENTS

We thank J.M. Barrios for technical assistance, and all members of the M. Bach-Elias' group for the comments about the manuscript. This work was supported by PGC grant no PB92-0004. C. Codony was recipient of a fellowship from PGC.

REFERENCES

1. Limbach, P. A., Crain, P. F. and McCloskey, J. A. *Nucleic Acids Res.*, **1994**, 22, 2183.
2. Schibler, U., Kelley, D. E. and Perry, R. P. *J. Mol. Biol.*, **1977**, 115, 695.
3. Wei, C. M. and Moss, B. *Biochemistry*, **1977**, 16, 1672.
4. Desrosiers, R. C., Friderici, K. H. and Rottman, F. M. *Biochemistry*, **1975**, 74, 4367.
5. Lavi, U., Fernandez-Munoz, R. and Darnell, J. E. *J. Nucleic Acids Res.*, **1977**, 4, 63.
6. Heilman, K. L., Leach, R. A. and Tuck, M. T. *Int. J. Biochem. Cell. Biol.*, **1996**, 28, 823.
7. Bokar, J. A., Rath-Shambaugh, M. E., Ludwiczak, R., Narayan, P. and Rottman, F. *J. Biol. Chem.*, **1994**, 269, 17697.
8. Bokar, J. A., Shambaugh, M. E., Polayes, D., Matera, A. G. and Rottman, F. M. *RNA*, **1997**, 3, 1233.
9. Bjork, G. R., Ericson, J. U., Gustafsson, C. E. D., Hagervall, T. G., Jonsson, Y. H. and Wikstrom, P. M. *Annu. Rev. Biochem.*, **1987**, 56, 263.
10. Maden, B. E. H. *Prog. Nucleic Acid Res. Mol. Biol.*, **1990**, 39, 241.
11. Shimba, S., Bokar, J. A., Rottman, F. and Reddy, R. *Nucleic Acids Research*, **1995**, 23, 2421.
12. Bringmann, P. and Lührmann, R. *FEBS Lett.*, **1987**, 213, 309.
13. Bochnig, P., Reuter, R., Bringmann, P. and Lührmann, R. *Eur. J. Biochem.*, **1987**, 168, 461.
14. Krainer, A. R. *Nucleic Acids Res.*, **1988**, 16, 9415.
15. Erlanger, B. F. and Beiser, S. M. *Proc. Natl. Acad. Sci. USA*, **1964**, 52, 68.
16. Steitz, J. *RNA Processing. Part A. General Methods.*, **1989**, 180, 468.